VIRX News and Press, Viracta Therapeutics Inc. From 04/21/23

2023-04-21 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, a...

2023-03-14 17:35:17 ET Major earnings expected after the bell on Wednesday include: Adobe ( ADBE ) UiPath ( PATH ) Zomedica Corp. ( ZOM ) Vaxart ( VXRT ) GrowGeneration Corp. ( GRWG ) For further details see: Notable earnings after Wednesd...

2023-03-13 16:50:51 ET Viracta Therapeutics press release ( NASDAQ: VIRX ): Q4 GAAP EPS of -$0.27 beats by $0.12 . Cash, cash equivalents and short-term investments totaled approximately $91.0 million as of December 31, 2022, which Viracta expects will be sufficient to...

Pivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV + ) lymphoma open at 70 sites globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 expected in the first half of 2023 Completed initial enrollment into the fourth dose level ...

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, a...

SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is...

The European Commission (EC) granted an orphan drug designation (ODD) to Viracta Therapeutics' ( NASDAQ: VIRX ) all-oral combination product candidate Nana-val (nanatinostat and valganciclovir) to treat diffuse large B-cell lymphoma (DLBCL). The EC previously granted ODD to N...

SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that the European Commission (EC) has granted an orphan drug...

Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV + recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC); enrollment into forth dose level is ongoing Anticipates clinical program updates from pivotal NAVAL-1 st...